-
-
-
-
-
-
-
VIVUS Reports Third Quarter 2019 Financial Results
-
-
-
-
-
-
-
VIVUS Reports Third Quarter 2018 Financial Results
-
-
-
-
-
-
-
VIVUS Announces 1-for-10 Reverse Stock Split
-
-
-
-
-
-
-
VIVUS Announces Positive Results from a Phase 1 Clinical Trial of VI-0106
-
-
-
-
-
-
-
VIVUS Reports First Quarter 2018 Financial Results
-
-
-
-
-
-
-
VIVUS Strengthens Executive Leadership Team
-
-
-
-
-
-
-
VIVUS Announces Tacrolimus Receives Orphan Drug Designation in the European Union for the Treatment of Pulmonary Arterial Hypertension
-
1,155,355 total articles have been posted to this entity.
Click Here to Sign-Up for StreetInsider.com Premium to View All

